To view this email as a web page, click here.
 
FDA clears generic valsartan to mitigate shortages
FDA approved a new generic of Novartis’ Diovan (valsartan) amid a shortage of the blood pressure drug.
Read more
 
FDA clears subcutaneous injectable to treat breast cancer
FDA approved a new subcutaneous injection to treat a certain type of early breast cancer.
Read more
 
Two reasons why payers love biosimilars
From our sister brand, Managed Healthcare Executive: With all eyes on drug prices, payers are looking to biosimilar agents to cut costs—and improve patient outcomes.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.